300158.SZ
振东制药
SZSE · Healthcare · C 制造业 · CN
CNY 5.10
−2.30%Year over year
Reported trailing growth
- Revenue
- -9.0%
- EBITDA
- —
- EBIT
- +62.8%
- EPS
- +77.1%
- Free cash flow
- +14.5%
- Operating cash flow
- +4.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -9.3%
- EBITDA
- +76.7%
- EBIT
- +62.9%
- Net income
- +77.3%
- EPS
- +76.9%
- Free cash flow
- -42.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026